TP53 and Miyoshi myopathy: JNJ-26854165 (141), also known as serdemetan, is an orally bioavailable compound that blocks the binding of the MDM2-p53 complex to the proteasome and inhibits the degradation of p53, thereby restoring p53-mediated apoptosis of tumor cells.372 Preclinical studies have shown that JNJ-26854165 exhibited strong activity against multiple myeloma (MM) cells both in vivo and in vitro.